Rat Acp5 (TartRate-resistant acid phosphatase type 5) ELISA Kit

Osteogenic-angiogenic coupling is promoted by the hypoxia-inducible factor 1-alpha (HIF-1 alpha) transcription factor, provoking interest in HIF activation as a therapeutic strategy to improve osteoblast mineralization and treat pathological osteolysis. However, HIF also enhances the bone-resorbing activity of mature osteoclasts. It is therefore essential to determine the full effect(s) of HIF on both the formation and the bone-resorbing function of osteoclasts in order to understand how they might respond to such a strategy. Expression of HIF-1 alpha mRNA and protein increased during osteoclast differentiation from CD14+ monocytic precursors, additionally inducing expression of the HIF-regulated glycolytic enzymes. However, HIF-1 alpha siRNA only moderately affected osteoclast differentiation, accelerating fusion of precursor cells. HIF induction by inhibition of the regulatory prolyl-4-hydroxylase (PHD) enzymes reduced osteoclastogenesis, but was confirmed to enhance bone resorption by mature osteoclasts. Phd2(+/-) murine osteoclasts also exhibited enhanced bone resorption, associated with increased expression of resorption-associated Acp5, in comparison with wild-type cells from littermate controls. Phd3(-/-) bone marrow precursors displayed accelerated early fusion, mirroring results with HIF-1 alpha siRNA. In vivo, Phd2(+/-) and Phd3(-/-) mice exhibited reduced trabecular bone mass, associated with reduced mineralization by Phd2(+/-) osteoblasts. These data indicate that HIF predominantly functions as a regulator of osteoclast-mediated bone resorption, with little effect on osteoclast differentiation. Inhibition of HIF might therefore represent an alternative strategy to treat diseases characterized by pathological levels of osteolysis. (C) 2017 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.

Objective: To identify and verify the histone modifier during osteoclastogene,vis. Methods: Murine macrophage-like cell line, RAW 264.7 cells, or marine hone marrow macrophages (BABA) were treated with a receptor activator of nuclear factor B ligand (RANKL) alone or RANKL with macrophage colony-stimulating factor (M-CSF), respectively to induce differentiation of osteoclast. Quantitative real-time polymerase chain reaction (qRT-PCR) was used to screen different arrays of histone demethylases. Chromatin immunoprecipitation (ChIP) assay was used to examine occupancy ()Dummy) domain containing 7 (Jmjd7) in the promoter regions of different osteoclast-related genes. Jmjd7 was knocked down using siRAA. Dentine slice assay was used to evaluate hone-resorptive functions. Results: Among the screened histone demethylases, Jmjd7 was significantly downregulated during differentiation of osteoclast. The occupancy of Jmjd7 at the promoter regions olosteoclast-related genes was also decreased. Knockdown of Jmjd7 in RAW 264.7 cells and BMMS enhanced differentiation of osteoclast and increased the expression of osteoclast-related genes, such as c-fos, Dc-stamp CtsK, Acp5, and Nfatc1. Bone resorptive functions of the cells were also increased. Conclusion: Our study shows that Jmjd7, a histone demethylase, functions as a negative regulator of osteoclastogenesis, and may he a therapeutic target of bone-realted diseases.